• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Modified vaccinia Ankara booster increases immunogenic response in Ebola Virus disease

byShayna BejaimalandShaidah Deghan, MSc. MD
May 8, 2016
in Infectious Disease, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Chimpanzee adenovirus 3 (ChAd3) vaccination boosted with modified vaccinia Ankara (MVA) elicited superior B- and T-cell immune responses to the Zaire ebolavirus than those induced by the ChAd3 vaccine alone.

2. The safety profile for MVA was found to be acceptable.

Evidence Rating Level: 2 (Good)

Study Rundown: Ebola virus disease (EVD) is a deadly infection with a high case fatality rate. In light of 2014’s West African Ebola outbreak, development and testing of an Ebola vaccine has been a priority. There has been some promising phase 1 and phase 3 vaccine results however these vaccines have a relatively short duration of action and are likely most helpful in limiting the spread of infection among close contacts of those with EVD. However, in earlier stages of an outbreak where transmission is unpredictable and new cases appear in geographically distinct locations, a vaccine of longer duration would be necessary. This phase 1 investigated the effect of adding a booster dose of MVA to the ChAd3 vaccine on the amount and duration of B-cell and T-cell immune responses as compared to ChAd3 vaccine.

The study results demonstrated that the ChAd3 vaccine that was boosted with MVA elicited higher levels and longer duration of virus-specific and neutralizing antibodies as compared to ChAd3 vaccination alone. The virus-specific antibody response remained positive 6 months after vaccination regardless of MVA booster status, however, those who received MVA boosters had a significantly higher titre levels.

Click to read the study in NEJM

Relevant Reading: Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

RELATED REPORTS

2 Minute Medicine Rewind October 16, 2017

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

2 Minute Medicine Rewind October 17, 2016

In-Depth [randomized controlled trial]: This phase 1 study was conducted at the Centre for Clinical Vaccinology and Tropical Medicine at the University of Oxford in the United Kingdom. Participants included healthy adults from 18 to 50. The 60 participants were administered the ChAd3 vaccine: 20 received a lower dose of 1×1010 viral particles, 20 received a dose of 2.5×1010 viral particles and 20 received the vaccine in a dose of 5×1010 viral particles. Ten participants from each dosage group were then given a single booster dose of MVA. These 30 individuals received another booster MVA dose 3 to 10 weeks following the priming immunization. Antibody responses were analyzed using 4 different IgG ELISAs. Separate T-cell assays (ELISPOT) were used to measure the T-cell response.

There were no safety concerns across all ChAd3 dosing regimens. Use of the MVA boosting routine resulted in a 12x increase in virus-specific antibodies (geometric mean titer, 9007) and a 5x increase in CD8+ T-cells. There were also significant increases in the titers of neutralizing antibodies (geometric mean titer, 139; p<0.001). These virus-specific antibodies remained positive in the participants’ blood for a 6-month duration, however those who received the MVA booster had significantly higher levels than those who did not.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ebola
Previous Post

Endometriosis linked to subsequent infertility risk

Next Post

Ozanimod can inhibit immune system response and improve ulcerative colitis symptoms

RelatedReports

Concomitant HPV vaccine administration equivalent to staggered schedule
Weekly Rewinds

2 Minute Medicine Rewind October 16, 2017

October 25, 2017
Concomitant HPV vaccine administration equivalent to staggered schedule
Infectious Disease

Recombinant vesicular stomatitis virus vaccine elicits anti-Ebola seroconversion

January 26, 2017
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Weekly Rewinds

2 Minute Medicine Rewind October 17, 2016

October 24, 2016
Ebola outbreak projected to exceed 20,000 cases by November
Infectious Disease

Recombinant vesicular stomatitis virus Ebola vaccine demonstrates immunogenicity

May 6, 2016
Next Post
Elective colectomy associated with improved survival in ulcerative colitis

Ozanimod can inhibit immune system response and improve ulcerative colitis symptoms

E-cigarettes linked to higher pediatric admissions

Swaddled infants at risk for developing SIDS

Swaddled infants at risk for developing SIDS

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.